eligibility_summary
Adults 18–70 with PTCL-NOS or AITL, progressive/no-response after ≥2 cycles first-line chemo or unable/unwilling to get IV chemo, ECOG ≤2, life ≥3 mo, measurable disease, adequate hepatic/marrow/renal/pulmonary/coagulation function and LVEF ≥50%. Exclude unresolved >G1 toxicity, active infection (incl. TB, zoster, pneumonia), HIV, active HBV/HCV unless controlled, major cardiac disease, GI malabsorption, uncontrolled systemic disease/bleeding/thrombosis, interstitial pneumonia, pregnancy/lactation, poor compliance risk.
trial_source
clinical_trials.gov from Dec 2, 2025
annotation_status
ai
ai_summary
Trial: single-arm R-GDP plus a PD-1 monoclonal antibody for relapsed/refractory PTCL-NOS and AITL. Drugs and mechanisms: • Rituximab (monoclonal antibody, anti-CD20): depletes CD20+ B cells via ADCC/CDC, modulating the AITL/PTCL microenvironment. • Gemcitabine (antimetabolite nucleoside analog): inhibits ribonucleotide reductase/DNA synthesis, inducing apoptosis in rapidly dividing cells. • Cisplatin (platinum DNA crosslinker): forms intra/interstrand DNA crosslinks → DNA damage–mediated apoptosis. • Dexamethasone (glucocorticoid): lympholytic, pro-apoptotic via glucocorticoid receptor, anti-inflammatory/cytokine suppression. • PD-1 monoclonal antibody (immune checkpoint inhibitor): blocks PD-1 on T cells to reverse exhaustion and enhance anti-tumor immunity. Targets/pathways: malignant peripheral T cells (including TFH-like AITL cells), tumor-supporting CD20+ B cells, PD-1/PD-L1 axis, DNA replication/repair, glucocorticoid signaling.